Company: AZN
Filing Date: 2025-04-04
Form Type: 6-K
Source: 0001654954-25-003894
Chunk: 9

Company: ASTRAZENECA PLC
Filing Date: 2025-04-04
Form: 6-K
Chunk 9
---
 Cancer J Clin . 2024;74(3):229-263.

8. WHO. International Agency of Cancer Research. Cancer Today. Breast. 2022. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/20-breast-fact-sheet.pdf. Accessed April 2025.

9. Iqbal N, et al. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int . 2014;852748.

10. Ahn S, et al. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med. 2020;54(1):34-44.

11. Sajjadi E, et al. Improving HER2 testing reproducibility in HER2-low breast cancer. Cancer Drug Resist . 2022;5(4):882-888.

12. Modi S, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387:9-20.

13. Eiger D, et al. The Exciting New Field of HER2-Low Breast Cancer Treatment. Cancers . 2021;13:1015.

#### Adrian Kemp

#### Company Secretary

#### AstraZeneca PLC
<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| AstraZeneca 
 PLC         |

Date: 04 April 2025

| By: /s/           
 Adrian Kemp       |
| Name:             
 Adrian Kemp       |
| Title:            
 Company Secretary |